Who is sponsoring NCT06989086?

NCT06989086 is sponsored by Virginia Commonwealth University.

What drugs are being tested in NCT06989086?

Interventions in NCT06989086: Fearless in Neuro-Oncology.

What condition does NCT06989086 study?

NCT06989086 studies Primary Malignant Brain Tumor, Glioblastoma (GBM), Astrocytoma, Oligodendroglioma, Caregiver.

Is NCT06989086 still recruiting?

NCT06989086 is currently recruiting now. Last updated 9 September 2025.

Last reviewed 2025-09-09 · How we verify

NCT06989086

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

FearLess in NeuroOncology

Recruiting now NA Last updated 9 September 2025

What this trial tests

NA trial testing Fearless in Neuro-Oncology in Primary Malignant Brain Tumor in 112 participants. Currently enrolling.

Timeline

24 June 2025

Primary endpoint
31 December 2028

31 December 2028

Quick facts

Lead sponsor	Virginia Commonwealth University
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	112
Start date	24 June 2025
Primary completion	31 December 2028
Estimated completion	31 December 2028
Sites	1 location across United States

Drugs / interventions tested

Fearless in Neuro-Oncology

Conditions studied

Primary Malignant Brain Tumor — all drugs for Primary Malignant Brain Tumor →
Glioblastoma (GBM) — all drugs for Glioblastoma (GBM) →
Astrocytoma — all drugs for Astrocytoma →
Oligodendroglioma — all drugs for Oligodendroglioma →

Sponsor

Virginia Commonwealth University

Who can join

18 and older, any sex, with Primary Malignant Brain Tumor or Glioblastoma (GBM). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The overarching goal of this project is to assess the feasibility, acceptability, and appropriateness of recruitment methods, target population, and a waitlist design to finalize the protocol of FearLess in primary malignant brain tumor patients and caregivers

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Virginia Commonwealth University trials

Trials by the same sponsor.

NCT05936931 — Young Adult-Mediated Intervention to Increase Colorectal Cancer Screening · NA · not yet recruiting
NCT07365839 — Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma · Phase 1 · not yet recruiting
NCT07178158 — Enhancing Addiction Treatment Through Psychoeducation · NA · not yet recruiting
NCT07531316 — Safety and Tolerability Study of VVZ-2471 in Healthy Volunteers · Phase 1 · not yet recruiting
NCT07426913 — Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06989086 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Virginia Commonwealth University
Last refreshed: 9 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06989086.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing